UBS has maintained a 'Neutral' rating for GSK, setting a target price of 1580 pence ahead of the third quarter results. Analyst Jo Walton highlighted concerns over the weak performance of GSK's vaccination business in the USA, particularly for Shingrix and Arexvy, leading to an uncertain outlook for the upcoming year.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.